NAPLEX (North American Pharmacist Licensure Examination) Practice Exam

Question: 1 / 1820

Which JAK inhibitor is mentioned first?

Baracitinib (Olumiant)

Upadacitinib (Rinvoq)

Tofacitinib (Xeljanz)

Tofacitinib (Xeljanz) is the JAK inhibitor mentioned first among the options provided. Tofacitinib was the first JAK inhibitor approved by the FDA for the treatment of rheumatoid arthritis, followed by the approvals of Baricitinib (Olumiant) and Upadacitinib (Rinvoq). Therefore, the correct answer is C.

Get further explanation with Examzify DeepDiveBeta

None of the above

Next Question

Report this question

Subscribe

Get the latest from Examzify

You can unsubscribe at any time. Read our privacy policy